Literature DB >> 8208421

Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis.

R E Steg1, D M Lefkowitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8208421     DOI： 10.1212/wnl.44.6.1180

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

2.  Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.

Authors:  K Harkness; S J Howell; G A Davies-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.

Authors:  Matthias Wittstock; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

5.  Case-control study of thromboembolic events associated with IV immunoglobulin.

Authors:  James B Caress; Lisa Hobson-Webb; Leah V Passmore; Anne P Finkbiner; Michael S Cartwright
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.